2019 ANTIBACTERIAL AGENTS IN CLINICAL DEVELOPMENT

an analysis of the antibacterial clinical development pipeline

World Health Organization

2019 ANTIBACTERIAL AGENTS IN CLINICAL DEVELOPMENT

an analysis of the antibacterial clinical development pipeline

World Health Organization

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline

ISBN 978-92-4-000019-3

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by Phoenix Design Aid

Printed in France

Contents

Acknowledgements v

Abbreviations and acronyms vi

Executive summary vii

1 INTRODUCTION 1

2 METHODS 3

2.1 Scope and inclusion/exclusion criteria 3

2.2 Search strategy 3

2.3 Assessment of activity against priority pathogens and innovation 4

2.3.1 Expected activity against priority pathogens 4

2.3.2 Innovation 4

3 AGENTS THAT OBTAINED MARKET AUTHORIZATION 6

4 AGENTS IN CLINICAL DEVELOPMENT 8

4.1 Antibiotics being developed against WHO priority pathogens 8

4.1.1 β-Lactams 11

4.1.2 Tetracyclines 15

4.1.3 Aminoglycosides 15

4.1.4 Topoisomerase inhibitors 15

4.1.5 FabI inhibitor 16

4.1.6 FtsZ inhibitor 17

4.1.7 Oxazolidinones 17

4.1.8 Macrolides and ketolides 17

4.1.9 Antibiotic hybrids 17

4.1.10 Polymyxins 18

4.2 Agents in development for treating TB infections 18

4.2.1 DprE1 inhibitors 20

4.3 Agents in development for treating *C. difficile* infections 21

4.4 Biological agents 22
4.4.1 Activity against S. aureus 23
4.4.2 Activity against P. aeruginosa 23
4.4.3 Activity against C. difficile 24
4.5 Agents that are not under active development or for which there is no recent information 24

5 DISCUSSION AND OUTLOOK 25

5.1 New agents insufficiently address a global need 25
5.2 The current clinical pipeline remains insufficient against priority pathogens 25
5.3 More innovative approaches are required, but there are scientific and economic challenges 26
5.4 Non-traditional approaches are attracting R&D interest 26
5.5 Market dynamics remain unfavourable 27
5.6 The pipeline outlook remains bleak 27

6 METHODOLOGICAL CONSIDERATIONS 28

6.1 Variable data quality 28
6.2 Limitations 28
6.3 Planned changes for the 2020 update 29

7 REFERENCES 30

Annex I Declaration of interests of advisory group members 35

Tab. 1 Antibiotics that gained market authorization between July 2017 and September 2019 7
Tab. 2 Antibiotics that are being developed against WHO priority pathogens 9
Tab. 3 Expected activity of β-lactams and β-lactam/BLI combinations against common β-lactamases 11
Tab. 4 Antibiotics for the treatment of TB and non-tuberculous mycobacteria in clinical development 19
Tab. 5 Antibiotics (small molecules) for the treatment of *C. difficile* infections in clinical development 21
Tab. 6 Biological antibacterial agents in clinical development 22
Tab. 7 Agents that are not under active development or for which there is no recent information 24
Fig. 1 Antibacterial agents in clinical development (Phase 1–3) viiii
Fig. 2 Summary of antibiotics in the clinical pipeline targeting the WHO priority pathogens 25

Acknowledgements

This publication was prepared by Sarah Paulin and Peter Beyer (WHO, Antimicrobial Resistance Division) with support from Ursula Theuretzbacher (Centre for Anti-infective Agents, Austria). Administrative support was provided by Sandra Kotur Corliss (WHO, Antimicrobial Resistance Division).

We would like to thank the members of the advisory group, which met in Geneva, Switzerland, on 30 September to 1 October 2019 to review the data, and to discuss and assess the antibacterial agents in the scope of this report. The advisory group consisted of:

- Mark Butler, principal research fellow, Centre for Clinical Research, University of Queensland, Australia (chair)
- Lloyd Czaplewski, director, Chemical Biology Ventures, United Kingdom of Great Britain and Northern Ireland
- Stephan Harbarth, full professor, Division of Infectious Diseases and Infection Control Programme, Geneva University Hospitals, WHO Collaborating Centre, Switzerland
- Jennie Hood, Global AMR R&D Hub, Germany (observer)
- François Franceschi, project leader, Asset Evaluation and Development, Global Antibiotic Research and Development Partnership, Switzerland (observer)
- Roman Kozlov, rector, Smolensk State Medical University, Russian Federation
- Christian Lienhardt, director of research, Institute for Research on Sustainable Development, France
- Norio Ohmagari, director, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Mical Paul, director, Infectious Diseases Institute, Rambam Health Care Campus, Israel
- John H. Rex, chief medical officer, F2G Ltd, United States of America
- Lynn Silver, owner, LL Silver Consulting, United States of America
- Guy Thwaites, director, Oxford University Clinical Research Unit, Viet Nam

We would like to thank Richard Alm and Ursula Theuretzbacher (WHO consultants, Antimicrobial Resistance Division) for their support for the data gathering and initial assessments of the antibacterial agents; Tiziana Masini (WHO, Global TB Programme) and Matteo Zignol (WHO, Global TB Programme) for their contributions to the tuberculosis research and development pipeline; and Maarten van der Heijden (WHO consultant, Antimicrobial Resistance Division) for reviewing the report.

We thank the following organizations for supporting the data collection: Access to Medicines Foundation, BEAM Alliance, Biotechnology Innovation Organization (BIO), Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), European Medicines Agency (EMA), Global Antibiotic Research and Development Partnership (GARDP), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID), Pew Charitable Trusts, Replenishing and Enabling the Pipeline for Anti-Infective Resistance (REPAIR) Impact Fund, TB Alliance, TB Union and Treatment Action Group (TAG).

We would also like to thank Jiang Jiandong (Chinese Academy of Medical Science and Peking Union Medical College) for providing data from China, Roman Kozlov for providing data from the Russian Federation and Norio Ohmagari for providing data from Japan.

The WHO Secretariat takes full responsibility for any omissions or errors in the data or other shortcomings in this document. We would welcome any feedback and additional information for future iterations of this pipeline analysis. Please send any comments to: antibacterialpipeline@who.int.

This document was edited by Giselle Weiss.

Financial support
Funding for this report was kindly provided by the Government of Austria.

Abbreviations and acronyms

ABSSSI	acute bacterial skin and skin structure infection
AWaRe	Access, Watch, and Reserve classification
BARDA	Biomedical Advanced Research and Development Authority
BIO	Biotechnology Innovation Organization
BLI	β-lactamase inhibitor
CAP	community-acquired pneumonia
CARB-X	Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator
cIAI	complicated intra-abdominal infection
CRAB	carbapenem-resistant *Acinetobacter baumannii*
CRE	carbapenem-resistant *Enterobacteriaceae*
CRPA	carbapenem-resistant *Pseudomonas aeruginosa*
cUTI	complicated urinary tract infection
DBO	diazabicyclooctane
DHFR	dihydrofolate reductase
DNA	deoxyribonucleic acid
DNDi	Drugs for Neglected Diseases initiative
DOI	declaration of interest
DprE1	decaprenylphosphoryl-β-D-ribose 2-epimerase
EMA	European Medicines Agency
EML	essential medicines list
ESBL	extended-spectrum β-lactamase
FDA	Food and Drug Administration
GARDP	Global Antibiotic Research and Development Partnership
HAP	hospital-acquired pneumonia
ICTRP	International Clinical Trials Registry
MIC	minimum inhibitory concentration
MmpL3	mycobacterial membrane protein large 3
MoA	mode of action
MRSA	methicillin-resistant *Staphylococcus aureus*
NBTI	novel bacterial topoisomerase II inhibitor
NDA	New Drug Application
NDM	New Delhi metallo-β-lactamase
NIH/NIAID	National Institutes of Health, National Institute of Allergy and Infectious Diseases
OPP	other priority pathogens on the WHO priority pathogens list ("high" and "medium" priority)
OXA	oxacillinase
PBP	penicillin-binding protein
PDF	peptide deformylase
PK/PD	pharmacokinetics/pharmacodynamics
R&D	research and development
REPAIR	Replenishing and Enabling the Pipeline for Anti-Infective Resistance
SME	small- or medium-sized enterprise and *Serratia marcescens* enzymes
TAG	Treatment Action Group
TB	tuberculosis
TB Alliance	Global Alliance for TB Drug Development
tet	tetracycline resistance encoding gene
UTI	urinary tract infection
VAP	ventilator-associated pneumonia
VIM	Verona integron-encoded metallo-β-lactamase

预览已结束，完整报告链接和二维码如下：
https://www.yunbaogao.cn/report/index/report?reportId=5_24844